Abstract
Recent patent disclosures reveal convergent strategies to modulate IL-17-driven pathology through complementary chemical and delivery modalities. Acidic small-molecule inhibitors, PEGylated derivatives, and antibody-functionalized lipid nanoparticles collectively address potency, exposure, and immune context. Together, these approaches outline an integrated framework for treating inflammatory diseases and immunosuppressive tumor microenvironments.